NVCR - Novocure Stock Soars Its Lung Cancer Electric Field Treatment Slows Progression To Brain Data Shows | Benzinga
Wednesday, Novocure Ltd (NASDAQ:NVCR) released data from the Phase 3 METIS clinical trial of Tumor Treating Fields (TTFields) therapy.
The study met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial (within skull/brain) progression for adult patients treated with TTFields therapy and supportive care compared to supportive care alone for 1-10 brain metastases from non-small cell lung cancer (NSCLC) following stereotactic radiosurgery.
Tumor Treating Fields is a cancer therapy that uses ...